Treatment of parkinsonism with levodopa.
D000328:Adult; D000368:Aged; D000856:Anorexia Nervosa / Q000139:chemically induced; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005684:Gait / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D013064:Speech Disorders / Q000188:drug therapy; D014202:Tremor / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D010648:Phenylacetates; D004295:Dihydroxyphenylalanine